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Abstract
CD1d is a non-classical major histocompatibility class 1-like molecule which primarily presents either microbial or
endogenous glycolipid antigens to T cells involved in innate immunity. Natural killer T (NKT) cells and a
subpopulation of gδ T cells expressing the Vg4 T cell receptor (TCR) recognize CD1d. NKT and Vg4 T cells function
in the innate immune response via rapid activation subsequent to infection and secrete large quantities of
cytokines that both help control infection and modulate the developing adaptive immune response. T regulatory
cells represent one cell population impacted by both NKT and Vg4 T cells. This review discusses the evidence that
NKT cells promote T regulatory cell activation both through direct interaction of NKT cell and dendritic cells and
through NKT cell secretion of large amounts of TGFb, IL-10 and IL-2. Recent studies have shown that CD1d-
restricted Vg4 T cells, in contrast to NKT cells, selectively kill T regulatory cells through a caspase-dependent
mechanism. Vg4 T cell elimination of the T regulatory cell population allows activation of autoimmune CD8+
effector cells leading to severe cardiac injury in a coxsackievirus B3 (CVB3) myocarditis model in mice. CD1d-
restricted immunity can therefore lead to either immunosuppression or autoimmunity depending upon the type of
innate effector dominating during the infection.
Introduction
Myocarditis is an inflammation of myocardium with
subsequent cardiomyocyte death, replacement fibrosis,
and cardiac dysfunction [1,2], is a significant cause of
sudden death in children and young adults [3-7], and
often follows cardiac infections (virus, bacteria, fungus,
worms) [8]. Enteroviruses and adenoviruses cause
approximately 80% of clinical viral myocarditis with
human cytomegalovirus, parvovirus, influenza virus, and
herpes simplex virus infection causing most of the
remainder [9]. Cardiac injury results from direct viral
injury to infected cardiocytes and from the host
response to infection[10]. Strong evidence exists for
immunopathogenic mechanisms of cardiac injury in
experimental models of coxsackievirus B3 (CVB3)
induced myocarditis. T cell depletion of mice dramati-
cally reduces animal mortality and cardiac inflammation
[11], and heart-specific, autoimmune CD8+ T cells iso-
lated from CVB3 infected mice [12] transfer myocarditis
into uninfected recipients. A major question is how the
virus activates these autoimmune CD8+ T cells.
Antigenic mimicry between CVB3 and cardiac myosin
forms the basis for the autoimmunity [13,14]. However,
some CVB3 variants replicate in the heart but fail to
activate autoimmunity [15]. The crucial difference
between the variants is that the pathogenic virus induces
CD1d up-regulation on hemopoietic and non-hemopoie-
tic cells but the non-pathogenic variant does not
[16-18], and this failure to up-regulate CD1d leads to
generation of T regulatory cells [19].
CD1 molecules and regulation of their expression
CD1 molecules belong to a family of non-polymorphic,
class I-like major histocompatibility complex (MHC)
molecules, which bind and present amphiphilic lipid
antigens to T cells for recognition [20]. The CD1 family
in humans and most other species are divided into
transmembrane Group 1 (CD1a,b,c), and Group 2
(CD1d) molecules [21,22]. An intermediate isoform
(CD1e) exists as a soluble molecule in the late endo-
some where it facilitates processing of complex glycoli-
pids for presentation by other CD1 isoforms [23].
Group 1 CD1 molecules are expressed on thymocytes,
dendritic cells, activated monocytes and B lymphocytes.
CD1d is expressed on these cells and additionally on
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T cells and non-hemopoietic cells including cardiac
myocytes and endothelial cells [16,22,24]. While structu-
rally similar to class I MHC molecules (consisting of a
single polypeptide chain coded by the CD1 gene and
associated with b2 microglobulin), antigen presentation
resembles class II MHC molecules since antigen loading
occurs in the endosome pathway and is TAP indepen-
dent [25-27]. The CD1 extracellular domain contains a
deep antigen binding groove comprised of up to four
hydrophobic pockets into which lipid tails of antigens
are inserted [28-30]. CD1b presents bacterial lipids
including mycobacterial mycolic acids [31], lipoarabino-
mannan [32], glucose monomycolate [33], and self-
glycosphingolipids such as GM1 ganglioside [34]. CD1a
and CD1c present bacterial phospholipids [35]. CD1d
presents a bacterial sphingolipid from Sphingomonas
[36], alphaproteobacterium from N. aromaticivorans
[37], glycolipids from B. burgdorferi [38], and a self-
sphingolipid isogloboside [39]. The sphingolipid a-galac-
tosylceramide (aGalCer) isolated from marine sponges,
is the classical CD1d ligand for activating NKT cells
[40]. CD1 molecules also bind and present other endo-
genous (self) glycolipid sulfatides [41-44]. Lysosomal a-
galactosidase A is highly effective in degrading endogen-
ous lipid antigens, normally limiting autoreactive NKT
cell responses [44]. However, infections inhibit a-galac-
tosidase A activity allowing endogenous lipid accumula-
tion and NKT cell activation. This means that CD1d
dependent innate immunity may be directed to both
exogenous and endogenous antigens during infections.
Group 1 CD1 molecules are not constitutively
expressed on myeloid precursors of dendritic cells, but
can be induced by signaling through TLR2 [45], TLR2/
TLR5 agonists, or cytokines (GM-CSF and IL-4) during
differentiation into immature dendritic cells [46]. CD1d
is constitutively expressed in dendritic cells at most
stages of differentiation, as well as on monocytes and
macrophage [47]. Unlike Group 1 CD1 molecules, CD1d
is not up-regulated by GM-CSF and IL-4 [24,48], but is
up-regulated by exposure to bacteria or viruses
[16,49,50]. Studies using M. tuberculosis found that both
signaling through TLR2 and cytokines (IFNg and TNFa)
were required for CD1d up-regulation on macrophage
both in vitro and in vivo [51]. Similarly, studies using L.
monocytogenes found that IFNb increases CD1d expres-
sion [52]. CVB3 infection augments CD1d expression on
macrophage, dendritic cells and T cells [18]. The virus
also causes de novo CD1d expression on non-hemopoie-
tic cells (cardiac endothelial cells and myocytes), but only
in non-hemopoietic cells actively replicating virus. Imme-
diately adjacent uninfected myocytes/endothelial cells
remain CD1d negative [16]. CD1d expression requires
TNFa, but TNFa treatment of uninfected endothelial
cells alone cannot induce CD1d [53], indicating that a
separate signal besides cytokine exposure is necessary for
de novo CD1d synthesis and that this signal must be gen-
erated through direct virus-cell interactions. In fact,
CVB3 binding to decay accelerating factor (DAF) one of
the two know cellular receptors for [54], provides the
essential secondary signal [17]. DAF is a glycosylpho-
sphatidylinositol (GPI)-anchored membrane glycoprotein
and its primary biological function is to prevent autolo-
gous complement induced cell injury by inactivating C3
[55-57]. Signaling through this molecule by C3 or CVB3
induces calcium flux and activation of the transcription
factor, NFAT [58,59]. CVB3 infection of DAF deficient
cells fails to induce CD1d expression [17], and blocking
NFAT activation either by use of cells expressing a domi-
nant-negative-NFAT or by cyclosporine A prevents
CD1d expression in virus infected cells. Thus, only cells
which are exposed to TNFa and bind virus to DAF on
the cell membrane will up-regulate CD1d.
While many microbial infections augment CD1
expression, other infectious agents suppress expression
of these molecules on dendritic cells and antigen pre-
senting cells [60-62]. In Leishmania, cytomegalovirus,
and herpes simplex virus infections, CD1 expression is
down-regulated. With HSV, modulation of CD1 was
dependent upon the amount of virus with low levels of
virus enhancing both type 1 and 2 CD1 expression on
human dendritic cells while high levels of virus sup-
pressed CD1 expression. In HSV, suppression correlated
with accumulation of intracellular viral protein and
interruption of CD1 recycling pathway. However, other
studies demonstrate that activating TLR7/8, TLR recog-
nizing single strand RNA and RNA viruses, block CD1
expression at the protein and mRNA levels [63]. Where
CD1-restricted immunity promotes host defense against
infection, inhibition of CD1 up-regulation can provide
an evasion mechanism for the microbes.
Role of CD1d in Innate Immunity and Infection
CD1d-dependent innate immunity is important in a
wide range of diseases. Infections with P. aeruginosa
[64], C. neoformans [65], Herpes Simplex virus [66],
Hepatitis C virus [50], and encephalomyocarditis virus
[67,68] make the disease substantially worse in animals
lacking CD1 or NKT cells. In contrast, clearance of RSV
is delayed in CD1d deficient mice [49,69]. CD1-
restricted cells appear to have minimal effects in
cytomegalovirus and lymphocytic choriomeningitis virus
infections [70]. In Novosphingobium aromaticivorans
infection in mice, CD1d presentation of alpha-glycuro-
nosylceramide from the bacterial cell wall activates NKT
cells and ultimately results in liver-specific autoimmu-
nity [37]. This means that CD1d-restricted effectors may
either have no, beneficial or detrimental functions
depending upon the infectious agent.
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There are two major populations of CD1-restricted T
cells. These are NKT cells and gδ T cells. NKT cells co-
express T cell receptors (TCR) and NK receptors. There
are two types of NKT cells. Type 1 NKT cells have a
TCR comprised of a single type of TCRa chain
(Va14Ja18 for mice and Va24Ja18 for humans) and
one of a limited number of distinct TCRb chains result-
ing in limited clonal diversity. These cells are usually
designated as invariant NKT (iNKT) cells. Type 2 NKT
cells use diverse TCR (non-Va14Ja18/Va24Ja18). Both
Type 1 and Type2 NKT cells are CD1d restricted
[71-73]. NKT cells comprise up to 2% of spleen, 20% of
mononuclear cells in the liver and 40% of CD3+ cells in
bone marrow in the mouse making these cells a major
component of the total T cell population [74,75]. NKT
cells have a constitutively activated phenotype and are
capable of rapidly secreting large amounts of cytokines
(IFN-g, IL-4, IL-17, IL-5, and IL-13) upon activation,
which can modulate many immunological processes,
including tumor immunity, maintenance of immunolo-
gic self tolerance, prevention of autoimmune disorders,
and protection from a variety of pathogens during
experimental infections [73,76,77]. Rapid cytokine secre-
tion occurs because cytokine mRNAs pre-exist in the
cells [78]. The presence of pro-inflammatory cytokines
(IL-12 and IL-12/IL-18) can dramatically reduce the
amount of CD1-dependent TCR signaling required for
NKT cell activation [79,80]. Type 1 NKT cells produce
IFNg and IL-2 which activates NK cells and dendritic
cells, enhancing antigen presentation [81,82]. Rapid
cytokine secretion by the NKT cells polarizes developing
adaptive immunity along the Th1/Th2 axis [83]. Both
Type 1 and Type 2 NKT cells can have a Th1 or Th2
phenotype with corresponding cytokine profiles, and
therefore may have either potentiating or protective
roles in infections and autoimmune diseases [84]. The
majority of reports indicate that Type 2 NKT cells are
protective in autoimmune diseases in mice including in
models of autoimmune diabetes in NOD mice [85], EAE
[86] and Con-A induced hepatitis [87]. Furthermore,
while type 1 NKT cells may increase tumor immunosur-
veillance, type 2 NKT cells may suppress anti-tumor
immunity [74,88].
NKT cells are not the only CD1 restricted lymphocyte.
Human gδ T cells recognize lipid antigens presented by
CD1 [89,90], and mouse gδ T cells recognize non-classi-
cal MHC antigens (T10/T22) [91,92]. gδ cells expressing
the Vg4 TCR recognize CD1d [16]. Within 2-4 days of
CVB3 infection, CD1d is rapidly up-regulated on cardiac
endothelial cells and myocytes and results in infiltration
of Vg4+ T cells into the myocardium [93]. As with NKT
cells, Vg4+ cells rapidly secrete large amounts of pro-
inflammatory cytokines including TNFa and IFNg
which establish an environment conducive to polarizing
the developing virus specific adaptive immune response
to a Th1 phenotype [94,95]. The Vg4+ cells also kill
CVB3 infected CD1d+ cardiocytes in a Fas-dependent
manner which aids in viral control by eliminating
infected cells early in the virus replication cycle. As with
NKT cells, gδ cells can interact with CD1 on dendritic
cells/macrophage resulting in enhanced antigen presen-
tation and cytokine release [96,97]. CVB3 infection of
mice lacking gδ T cells results in increased virus titers
in the heart but little or no cardiac inflammation, ani-
mal mortality, or heart-specific autoimmunity[98-100]
making gδ cells essential in the pathogenesis of CVB3
infections.
Several cases of clinical cardiomyopathy where gδ cells
dominate the inflammatory infiltrate have been reported
[101-103] suggesting that these innate effectors can be
directly pathogenic. More often, gδ cells would impact
myocarditis through their effects on the antigen-specific,
adaptive immune response. In this laboratory’s mouse
model of CVB3 induced myocarditis, infection activates
heart-specific, autoimmune CD8+ cytolytic T lympho-
cytes [12,100,104,105] which kill uninfected cardiocytes
through recognition of cardiac myosin epitopes [14] and
can adoptively transfer myocarditis into uninfected reci-
pients [106]. These autoimmune CD8+ effectors are the
primary cause of cardiac injury. In vivo generation of
autoimmune CD8+ cells requires activated Vg4 cells and
mice lacking either the Vg4 or all gδ cells do not gener-
ate autoimmunity [100]. Thus, the primary role of Vg4
cells in CVB3 induced myocarditis is to facilitate auto-
immunity induction.
Role of CD1d in CD4+CD25+ regulatory T cell response
Regulatory T cells (Tregs) are important negative
immune modulators, constitute up to 10% of peripheral
CD4+ T cells in naive mice and humans, and express
CD25 (IL-2 receptor a chain) [107-109]. Several subsets
of T regulatory cells have been described and these can
basically be divided into natural (nTreg) and inducible
(iTreg) populations. The nTreg cells arise in the thymus
during normal T cell ontogeny as CD4+CD25+ cells
and depend upon expression of the FoxP3 transcription
factor. Indeed FoxP3 expression is crucial to the immu-
nosuppression activity of these nTreg since transduction
of exogenous FoxP3 into CD4+CD25- cells is sufficient
to convert these cells into CD4+CD25+ Treg cells [108].
Developing T cells with high affinity TCR for self anti-
gens are most probably committed to the nTreg line.
While most ab TCR+ cells (exclusive of NKT cells)
developing in the thymus enter the periphery as naïve
cells, nTreg cells are functionally mature when leaving
the thymus and do not require antigen exposure periph-
erally to generate immunosuppressive activity. While
FoxP3 is necessary for conversion of CD4+ cells to Treg
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cells, IL-2 is required for Treg cell maintenance/survival.
Animals lacking either CD25 (IL-2R) or IL-2 develop
lymphoproliferative and autoimmune diseases [110]
associated with a decrease in Treg cells. Although the
transcription factor NFAT normally increases expression
of IL-2and IFNg while decreasing expression of CD25
and CTLA4, NFAT complexed with FoxP3 has the
opposite effect, decreasing IL-2/IFNg and increasing
CD25/CTLA4 expression. In addition to nTreg cells,
inducible regulatory T cells (iTreg) can be converted
from effector T cell populations in the periphery subse-
quent to antigen challenge. These iTreg cells are
CD4+CD25+ but can either be FoxP3+ or FoxP3- [111].
Both iTreg and nTreg cells can secret either IL-10 (Tr1)
or TGFb (Th3) cytokines [111]. Treg cells express simi-
lar chemokine receptor patterns as effector T cells and
can migrate to peripheral lymphoid tissues and inflam-
matory sites similarly to the effector population [108].
There are three general hypothesized mechanisms for
Treg cell suppression of immunity [108]. First, T reg
cells may bind to and out-compete effector T cells for
MHC-antigen complexes on dendritic cells and effec-
tively block antigen presentation to the effector T cell
populations. Secondly, direct Treg-dendritic cell interac-
tions through CTLA4 can down-regulate accessory
molecule expression (CD80/CD86) on the dendritic cells
making them less effective in antigen presentation.
Third, Treg cells can either kill or inhibit T cell differ-
entiation. TGFb produced by Treg cells will activate
NOTCH and its downstream target gene, Hes1, which
suppresses gene expression in T cells [111]. IL-10 blocks
CD2, CD28 and ICOS signaling in T cells and SOCS3
signaling in monocytes resulting in reduced T cell pro-
liferation and cytokine response [112].
Treg cells play an important role in preventing
autoimmunity in myocarditis [19,113,114]. Two CVB3
variants have been identified which differ by a single
non-conserved mutation in the VP2 capsid protein in a
region associated with DAF binding [15]. One variant,
designated H3, binds with high avidity to DAF, causes
calcium flux and NFAT activation, induces CD1d
expression in the heart and activates Vg4 cells
[16,17,19,59]. The other variant, designated H310A1,
binds with low affinity to DAF, fails to activate NFAT,
does not up-regulate CD1d expression in the heart, and
does not activate Vg4 cells. While H3 virus induces
autoimmune CD8 T cells and causes severe myocarditis,
the H310A1 virus fails to induce autoimmunity and
induces minimal cardiac injury despite high virus titers
in the heart [115]. The primary difference between the
two virus infections is that H310A1 infection activates
CD4+CD25+FoxP3+ Treg cells which are absent in H3
infected mice [19].
Innate effector T cells control Treg cell responses.
Although somewhat controversial, various reports indi-
cate that iNKT cells suppress autoimmunity by promot-
ing T regulatory cell activation. Studies investigating
oral tolerance to nickel demonstrated that antigen pre-
senting cells interact with type 1 NKT cells through
CD1d causing the NKT cells to secrete IL-4 and IL-10
and activate Treg cells [116-118]. Similar studies found
that T regulatory cells fail to generate in CD1dKO mice
[119] and iNKT KO mice [119]. Other studies show
that aGalCer, a well known and specific NKT CD1d-
restricted ligand, increases Treg cell numbers in vivo
[120] and can suppress autoimmune diabetes in NOD
mice [121-123]. NKT cells secret high levels of TGFb
and IL-10 [124,125] which alter dendritic cell (DC) cyto-
kine (IL-10) and accessory molecule (CD40, CD80 and/
or CD86) expression [126-128] that favors T regulatory
cell responses [129,130].
A number of reports indicate that gδ T cells can also
affect Treg cell responses. IL-23 activated gδ cells pre-
vent conversion of effector T cells to iTreg cells [131].
Similarly gδ cells reduce IL-10 producing Treg cells in
the lung in an asthma model gδ cells [132]. Vg2Vδ2
cells prevent IL-2 induced expansion of CD4+CD25
+FoxP3+ T [133]. Therefore, while many studies suggest
that NKT cells promote Treg cell activation and protect
from autoimmunity, it appears that gδ T cells can have
the opposite effect and promote autoimmunity/inflam-
mation through inhibiting T regulatory cell activity. As
with NKT cells, the mechanism by which gδ T cells
modulate Treg cell responses can be diverse and include
alterations in antigen presenting cells which prevent
Treg cell activation, and suppression of IL2 needed for
Treg cell maintenance. This laboratory has recently
reported an additional mechanism for gδ T cell modula-
tion of Treg cell responses using two coxsackievirus B3
variants which differ by a single non-conserved amino
acid in the VP2 capsid protein [15]. These studies show
that the non-pathogenic variant induces a potent T reg-
ulatory cell (CD4+CD25+FoxP3+) response which is
absent during infections with the pathogenic virus [19].
Although H3 infected mice normally have few
CD4+CD25+FoxP3+ cells, H3 infection of gδ cell defi-
cient mice results in significant increases in Treg cells
and suppression of myocarditis. Therefore, this study, as
others mentioned above, find that gδ cells antagonize
Treg cell responses and promote autoimmunity. Further
studies demonstrate that a subpopulation of Treg cells
in gδ deficient mice express high levels of CD1d, that
the CD1d+ Treg cells are substantially more immuno-
suppressive on a per cell basis than CD1d- Treg cells,
and that Vg4+ cells selectively kill the CD1d+ Treg cells
in a CD1d and caspase-dependent manner [10].
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Conclusions
Innate immunity is crucial to anti-microbial host
defense as it helps control infectious agents until a more
potent microbe-specific, adaptive immune response can
be generated. However, the innate response is also
important in molding the nature of the adaptive
immune response. CD1 molecules, as members of the
non-classical MHC family, are intimately involved in
innate immunity. NKT and a subset of gδ T cells are
CD1 restricted. Figure 1 provides a schematic of the
interactions between innate effectors and the adaptive
immune response through CD1d. This raises the inter-
esting question of why two innate effector populations
would exist which respond to the same type of antigen
presenting molecule, especially since CD1 molecules
have limited diversity and are therefore more likely to
present less heterogeneous antigens than classical MHC
antigens. Two possibilities are that CD1-restricted NKT
and gδ T cells have redundant functions or that each
type of CD1-restricted effector has a distinct role in the
immune response. One potential reason for redundancy
is that NKT and gδ cells tend to concentrate in different
tissues. NKT cells comprise 20-30% of liver and bone
marrow T cells but are generally absent in intestinal
epithelial lymphocytes (IEL) [134]. In contrast, gδ con-
centrate in epithelia of skin, intestine and reproductive
tract where these cells can comprise up to 50% of the
T cells [135]. This distribution could imply that CD1
presentation of microbial or self antigens will preferen-
tially activate NKT or gδ cells depending upon the tissue
involved. In peripheral lymphoid organs where both
NKT and gδ cells are present, other factors must deter-
mine if CD1-dependent NKT or gδ cell responses predo-
minate. What these factors are is not known. One
possibility is that while CD1 presents a variety of glyco-
lipid antigens, NKT and gδ cells recognize distinct sets
of these antigens. In this case, CD1d might exclusively
activate only NKT or gδ cells depending upon which
glycolipid antigens are presented. A second possibility is
that the binding avidity for CD1d-antigen complexes
differ for NKT and gδ cells meaning that the innate
effector with the stronger binding avidity would domi-
nate. The relevant point is that the balance between
NKT and gδ activation can be the deciding factor
between self-tolerance and autoimmunity. The major
unresolved question is what decides whether gδ or NKT
cells dominate in an innate response where CD1 is
up-regulated.
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